Multimodal Nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain

Biomaterials

Volumn 35, Issue 6, 2014, Pages 1967-1976

  Jaruszewski, Kristen M ^a,b,d   Curran, Geoffry L ^b   Swaminathan, Suresh K ^a   Rosenberg, Jens T ^e   Grant, Samuel C ^e,f   Ramakrishnan, Subramanian ^e,f   Lowe, Val J ^c   Poduslo, Joseph F ^b   Kandimalla, Karunya K ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC   (United States)

^d FLORIDA A AND M UNIVERSITY   (United States)

^e FLORIDA STATE UNIVERSITY   (United States)

^f FAMU FSU COLLEGE OF ENGINEERING   (United States)

Author keywords

Alzheimer's disease (AD); Brain targeting; Cerebrovascular amyloid (CVA); Magnetic resonance imaging (MRI); Nanovehicles; Single photon emission computed tomography (SPECT)

Indexed keywords

ALZHEIMER'S DISEASE; ANTI-INFLAMMATORIES; BRAIN TARGETING; CEREBRAL AMYLOID ANGIOPATHY; CEREBROVASCULAR AMYLOID (CVA); MAGNETIC RESONANCE IMAGING CONTRAST AGENTS; NANOVEHICLES; QUARTZ CRYSTAL MICROBALANCE WITH DISSIPATION MONITORING;

BLOOD VESSELS; GLYCOPROTEINS; MAGNETIC RESONANCE IMAGING; MICROCIRCULATION; NEURODEGENERATIVE DISEASES; PATHOLOGY; PROTEINS;

SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY;

AF 647; ALEXAFLUOR 647; AMYLOID PROTEIN; CEREBROVASCULAR AMYLOID; CONTRAST MEDIUM; CURCUMIN; DEXAMETHASONE; DUTCHA BETA 40; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; IMMUNOGLOBULIN G4.1 NANOPARTICLE; IODINE 125; NANOCARRIER; PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL WALL; BRAIN; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN REGION; BRAIN VASCULITIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGHT SCATTERING; MOUSE; MULTIMODAL NANOPROBE; NANOPROBE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN TARGETING; QUARTZ CRYSTAL MICROBALANCE; RADIOACTIVITY; RADIOIODINATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASCULAR AMYLOIDOSIS; ZETA POTENTIAL;

ALZHEIMER'S DISEASE (AD); BRAIN TARGETING; CEREBROVASCULAR AMYLOID (CVA); MAGNETIC RESONANCE IMAGING (MRI); NANOVEHICLES; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT);

ALZHEIMER DISEASE; ANIMALS; BRAIN; CELL LINE; CEREBRAL AMYLOID ANGIOPATHY; CHITOSAN; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; PLAQUE, AMYLOID; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84890133352     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.10.075     Document Type: Article

References (25)

1. Calhoun M.E., Burgermeister P., Phinney A.L., Stalder M., Tolnay M., Wiederhold K.H., et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A 1999, 96:14088-14093.
2. Jack C.R., Marjanska M., Wengenack T.M., Reyes D.A., Curran G.L., Lin J., et al. Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research. Neuroscientist 2007, 13:38-48.
3. Poduslo J.F., Hultman K.L., Curran G.L., Preboske G.M., Chamberlain R., Marjanska M., et al. Targeting vascular amyloid in arterioles of Alzheimer disease transgenic mice with amyloid beta protein antibody-coated nanoparticles. JNeuropathol Exp Neurol 2011, 70:653-661.
4. Poduslo J.F., Ramakrishnan M., Holasek S.S., Ramirez-Alvarado M., Kandimalla K.K., Gilles E.J., et al. Invivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. JNeurochem 2007, 102:420-433.
5. Weksler B.B., Subileau E.A., Perriere N., Charneau P., Holloway K., Leveque M., et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 2005, 19:1872-1874.
6. Jingou J., Shilei H., Weiqi L., Danjun W., Tengfei W., Yi X. Preparation, characterization of hydrophilic and hydrophobic drug in combine loaded chitosan/cyclodextrin nanoparticles and invitro release study. Colloids Surf B Biointerfaces 2011, 83:103-107.
7. Agyare E.K., Curran G.L., Ramakrishnan M., Yu C.C., Poduslo J.F., Kandimalla K.K. Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy. Pharm Res 2008, 25:2674-2684.
8. Saha T.K., Ichikawa H., Fukumori Y. Gadolinium diethylenetriaminopentaacetic acid-loaded chitosan microspheres for gadolinium neutron-capture therapy. Carbohydr Res 2006, 341:2835-2841.
9. Shikata F., Tokumitsu H., Ichikawa H., Fukumori Y. Invitro cellular accumulation of gadolinium incorporated into chitosan nanoparticles designed for neutron-capture therapy of cancer. Eur J Pharm Biopharm 2002, 53:57-63.
10. Swaminathan S.K., Roger E., Toti U., Niu L., Ohlfest J.R., Panyam J. CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. JControl Release 2013, 280-287.
11. Poduslo J.F., Curran G.L., Wengenack T.M., Malester B., Duff K. Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2001, 8:555-567.
12. Poduslo J.F., Curran G.L. Increased permeability of superoxide dismutase at the blood-nerve and blood-brain barriers with retained enzymatic activity after covalent modification with the naturally occurring polyamine, putrescine. JNeurochem 1996, 67:734-741.
13. Rowatt E., Williams R.J. The interaction of cations with the dye arsenazo III. Biochem J 1989, 259:295-298.
14. Jaruszewski K.M., Ramakrishnan S., Poduslo J.F., Kandimalla K.K. Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer's disease amyloid protein. Nanomedicine 2012, 8:250-260.
15. Fu R., Brey W.W., Shetty K., Gor'kov P., Saha S., Long J.R., et al. Ultra-wide bore 900 MHz high-resolution NMR at the National High Magnetic Field Laboratory. JMagn Reson Imaging 2005, 177:1-8.
16. Rosenberg J.T., Cisneros B.T., Matson M., Sachi-Kocher A., Sokoll M., Calixto Bejarano F., et al. Encapsulated gadolinium and dysprosium ions within ultrashort carbon nanotubes for MR microscopy at 11.75 and 21.1 T. Contrast Media Mol Imaging 2003, (In Press).
17. Rosenberg J.T., Sachi-Kocher A., Davidson M.W., Grant S.C. Intracellular SPIO labeling of microglia: high field considerations and limitations for MR microscopy. Contrast Media Mol Imaging 2012, 7:121-129.
18. Rosenberg J.T., Kogot J.M., Lovingood D.D., Strouse G.F., Grant S.C. Intracellular bimodal nanoparticles based on quantum dots for high-field MRI at 21.1 T. Magn Reson Med 2010, 64:871-882.
19. Webb A.G., Grant S.C. Signal-to-noise and magnetic susceptibility trade-offs in solenoidal microcoils for NMR. JMagn Reson B 1996, 113:83-87.
20. Ma Y., Hof P.R., Grant S.C., Blackband S.J., Bennett R., Slatest L., et al. Athree-dimensional digital atlas database of the adult C57BL/6J mouse brain by magnetic resonance microscopy. Neuroscience 2005, 135:1203-1215.
21. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid invivo. JBiol Chem 2005, 280:5892-5901.
22. Goel A., Kunnumakkara A.B., Aggarwal B.B. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 2008, 75:787-809.
23. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. JNeurosci 2001, 21:8370-8377.
24. Yanagisawa D., Amatsubo T., Morikawa S., Taguchi H., Urushitani M., Shirai N., et al. Invivo detection of amyloid beta deposition using (1)(9)F magnetic resonance imaging with a (1)(9)F-containing curcumin derivative in a mouse model of Alzheimer's disease. Neuroscience 2011, 184:120-127.
25. Previti M.L., Zhang W., Van Nostrand W.E. Dexamethasone diminishes the pro-inflammatory and cytotoxic effects of amyloid beta-protein in cerebrovascular smooth muscle cells. JNeuroinflammation 2006, 3:18.